ARPO Key Statistics, Chart & Performance
The current stock price of ARPO is 2.2 null. In the past month the price increased by 3.77%. In the past year, price increased by 65.41%.
ARPO Latest News, Press Relases and Analysis
ARPO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About ARPO
Company Profile
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Loveland, Ohio and currently employs 12 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The firm is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The firm's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
Company Info
Aerpio Pharmaceuticals Inc
10663 LOVELAND-MADEIRA ROAD #168
Loveland OHIO 45242 US
CEO: Joseph Gardner
Employees: 12
Phone: 15139851920.0
Aerpio Pharmaceuticals Inc / ARPO FAQ
Can you describe the business of Aerpio Pharmaceuticals Inc?
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Loveland, Ohio and currently employs 12 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The firm is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The firm's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
What is the stock price of Aerpio Pharmaceuticals Inc today?
The current stock price of ARPO is 2.2 null. The price decreased by -0.9% in the last trading session.
Does Aerpio Pharmaceuticals Inc pay dividends?
ARPO does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARPO stock?
ARPO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for Aerpio Pharmaceuticals Inc?
Aerpio Pharmaceuticals Inc (ARPO) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for Aerpio Pharmaceuticals Inc?
Aerpio Pharmaceuticals Inc (ARPO) has a market capitalization of 104.85M null. This makes ARPO a Micro Cap stock.
Can you provide the ownership details for ARPO stock?
You can find the ownership structure of Aerpio Pharmaceuticals Inc (ARPO) on the Ownership tab.
ARPO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARPO. When comparing the yearly performance of all stocks, ARPO is one of the better performing stocks in the market, outperforming 85.4% of all stocks.
ARPO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARPO. No worries on liquidiy or solvency for ARPO as it has an excellent financial health rating, but there are worries on the profitability.
ARPO Financial Highlights
Over the last trailing twelve months ARPO reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -355.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ARPO Forecast & Estimates
2 analysts have analysed ARPO and the average price target is 47.94 null. This implies a price increase of 2079.09% is expected in the next year compared to the current price of 2.2.
For the next year, analysts expect an EPS growth of 33.81% and a revenue growth -100% for ARPO